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Summary
The 155-kDa glycoprotein, complement factor H (CFH), is a regulator
of complement activation that is abundant in human plasma. Three-
dimensional structures of over half the 20 complement control protein (CCP)
modules in CFH have been solved in the context of single-, double- and
triple-module segments. Proven binding sites for C3b occupy the N and C
termini of this elongated molecule and may be brought together by a bend in
CFH mediated by its central CCP modules. The C-terminal CCP 20 is key to
the ability of the molecule to adhere to polyanionic markers on self-surfaces
where CFH acts to regulate amplification of the alternative pathway of
complement. The surface patch on CCP 20 that binds to model glycosami-
noglycans has been mapped using nuclear magnetic resonance (NMR), as has
a second glycosaminoglycan-binding patch on CCP 7. These patches include
many of the residue positions at which sequence variations have been linked
to three complement-mediated disorders: dense deposit disease, age-related
macular degeneration and atypical haemolytic uraemic syndrome. In one
plausible model, CCP 20 anchors CFH to self-surfaces via a C3b/polyanion
composite binding site, CCP 7 acts as a ‘proof-reader’ to help discriminate self-
from non-self patterns of sulphation, and CCPs 1–4 disrupt C3/C5 convertase
formation and stability.
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Introduction
Factor H is a 155-kDa soluble glycoprotein regulator of the
complement system. It is abundant in plasma and can asso-
ciate with host cell membranes and other self-surfaces via
recognition of polyanions such as glycosaminoglycans
(GAGs) and sialic acid [1]. Through intervention at the level
of the alternative-pathway C3 and C5 convertase enzymes it
modulates both fluid-phase and surface-associated comple-
ment amplification. Factor H works in several ways [2]: it
competes with factor B for binding to C3b, thus impeding
formation of alternative-pathway C3 convertases (C3bBb);
when bimolecular convertase complexes do succeed in
assembling, CFH accelerates their subsequent dissociation
(decay); CFH also accelerates decay of the alternative-
pathway C5 convertase (C3b2Bb); and CFH is a co-factor for
factor I-mediated proteolytic cleavage of C3b to iC3b. As
well as having binding sites for C3b, polyanions, and factor I,
CFH reportedly binds to C-reactive protein (CRP) [3], fibro-
modulin [4] and adrenomedullin [5]. Finally, it is bound by
proteins borne on microorganisms that surface-sequester
CFH to evade complement [6].
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The structure of factor H
The 1213 amino acid residues of mature CFH (155 kDa)
[7,8] consist of 20 short consensus repeats (SCRs), each of
~60 residues [9]. A multiple alignment of the 20 SCRs
(Fig. 1) highlights four invariant Cys residues and a near-
invariant Trp residue between Cys(III) and (IV). This
consensus sequence also occurs multiple times in other
members of the regulators of complement activation (RCA)
family [10], including C4b-binding protein (C4 BP),
complement receptor type 1 (CD35), decay accelerating
factor (CD55), membrane co-factor protein (CD46) and a
set of CFH-related proteins. Within CFH, ‘linkers’ of
between three and eight residues lie between Cys(IV) (last
residue) of one SCR and Cys(I) (first residue) of the next
SCR. Each of the 20 SCRs (plus one or two residues within
the linkers at either end) is presumed to fold into a distinct
three-dimensional (3D) structure termed the complement
control protein module (CCP) [11], stabilized by Cys(I)–
Cys(III), Cys(II)–Cys(IV) disulphide linkages.
Structures rich in b-sheet were predicted originally for
SCRs/CCPs based on sequence analysis [12,13]. While circu-
lar dichroism spectra of CFH were uninterpretable (due to
contributions from the 40 putative disulphide bonds) [14],
Fourier-transformed infrared spectroscopy [15] confirmed
extensive b-sheet in CFH and a paucity of a-helices. Infrared
spectroscopy also demonstrated rapid exchange of backbone
amide protons with solvent, indicative of an elongated struc-
ture for CFH in which the multiple CCPs do not, in general,
contribute to a common globular arrangement. This
inference of an extended structure concurs with electron
microscopy, small-angle X-ray scattering and analytical
ultracentrifugation studies of C4 BP, CFH and other RCAs
[16–19]. Currently, a ‘folded-back’ model for CFH is
favoured, bringing together its N- and C-terminal regions
[20].
There are 3D structures currently available for 11 of the 20
CFH CCPs that have been expressed recombinantly as single,
double or triple modules [21–28] (and unpublished data);
and reliable homology-based models have been produced
for several others [29]. Each CCP has an ovoid structure
(Fig. 2), of dimensions approximately 40 Å by 15 Å by 10 Å.
Fig. 1. Multiple sequence alignment of 20 short consensus repeats in sequence of complement factor H (CFH). One-letter codes used throughout;
invariant Cys residues and almost invariant Trp residue are highlighted. Arrows indicate other well-conserved residues. Each short consensus repeat
(SCR) probably folds into a complement control protein (CCP) module; horizontal lines indicate disulphides within CCP module.
Fig. 2. Cartoon showing three-dimensional structure of the
complement control protein (CCP) module pair, complement factor
H (CFH) 19–20. Cys side-chains (green and orange) drawn [PyMol
(Warren L. DeLano, ‘The PyMOL Molecular Graphics System’,
DeLano Scientific LLC, San Carlos, CA, USA. http://www.pymol.org)]
in space-fill representation; the three Trp side-chains (red) present are
drawn in stick representation. Module 19 is typical of CCP modules;
CCP 20 (lacking the consensus Trp) is less elongated than CCP 19.
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Five extended stretches of residues (that often form
b-strands and small antiparallel b-sheets) run back or forth
in a direction that is approximately parallel with the long axis
of the CCP. Thus the module’s N and C termini occupy
opposite poles consistent with a ‘head-to-tail’ arrangement
of adjacent modules. Indeed, 3D structures of the module
pair consisting of CCPs 15 and 16 (i.e. CFH 15–16) [24], and
of the triple-module CFH 6–8 [28], are elongated with small
intermodular buried surface areas. Bulges or loops, corre-
sponding to insertions and areas of low sequence conserva-
tion, project laterally from the body of the module
potentially contributing to binding specificity. Because
stabilizing interactions between neighbouring modules are
limited, intermodular flexibility is possible. The degree of
overall flexibility of CFH is unknown, as are the extents of
any conformational changes upon interaction with binding
partners.
Binding sites of factor H for C3b
The N-linked glycans of CFH are dispensable for comple-
ment regulation [30], although whether they modulate
interactions electrostatically between CFH and surface-
borne polyanions requires further investigation. Early
mapping of functional sites to specific CFH CCP modules
focused on a 38-kDa tryptic N-terminal fragment, with
fluid-phase C3b-binding and co-factor activity [31,32], cor-
responding to CCPs 1–5 plus part of CCP 6. A 42-kDa CFH
splice variant (CFH-like 1) containing CCPs 1–7 is similarly
able to regulate fluid-phase complement [33]. To pinpoint
key functional modules, fluid-phase co-factor activity was
measured for (non-purified) module-deletion and trunca-
tion mutants of the 38-kDa fragment expressed recombi-
nantly and secreted from Chinese hamster ovary cells [34]
(see Fig. 3). The results imply that the four N-terminal CCPs
are required for full co-factor activity in the fluid phase,
although CFH 1–3 (and to a lesser extent CFH 2–4) retained
residual activity. A subsequent study [35] (involving con-
structs prepared in a baculovirus expression vector) largely
reinforced these findings: while the CFH 1–4 construct dis-
played full fluid-phase co-factor activity the triple-module
constructs CFH 1–3, CFH 2–4, CFH 1–2, 4 and CFH 1, 3–4
lacked it, as did the four-module construct CFH 1, 6–7, 4
(where CCPs 6 and 7 replace CCPs 2 and 3), and CFH 1–4
with non-native linker lengths. Subsequently, CCPs 1–4 were
also shown to be required for the decay accelerating activity
of this molecule, although full-length CFH is apparently
~100-fold more potent than CFH 1–4 or CFH-like 1 in this
respect. In summary [43], the N-terminal four CCPs of CFH
are necessary and sufficient to engage with C3b and C3 con-
vertase in the fluid phase and thereby regulate amplification
of the cascade via the alternative pathway. Interestingly,
patients with an amino acid residue deletion in CCP 4 devel-
oped dense deposit disease [44], a renal pathology also seen
in factor H-deficient humans, pigs and mice [45].
Further C3b-binding sites were identified using
immunoaffinity-purified module-deletion CFH mutants
from a baculovirus expression vector [41]. Constructs lacked
(D) modules: 2; 5; 1–5; 6–10; 11–15; 16–20; 1–10; or 11–20.
All these deletion mutants exhibited C3b-co-factor activity
except CFHD2, CFHD1–5 and CFHD1–10. Crucially,
CFHD1–5 (and CFHD2) none the less retained some binding
affinity for cell-surface (sheep erythrocyte)-bound C3b
(csbC3b), demonstrating that CFH CCPs other than
modules 1–4 bind C3b. Deletions of CCPs 16–20 decimated
affinity for csbC3b, thus implicating a C-terminal region of
CFH as a second C3b-binding site. A third C3b-binding site
was suggested because CFHD6–10 exhibited a decreased
affinity for csbC3b, similar to that of CFHD1–5.
An antibody (131X) specific for CCPs 8–15 weakened
interactions of full-length CFH with csbC3b [46], suggest-
ing that a third C3b-binding region lies in these CCPs. Sub-
sequently Jokiranta et al. [36] investigated binding of
purified CFH constructs, cloned in a baculovirus system, to
C3b, and its fragments C3c and C3d, attached to Biacore
‘CM5’-chips. In these surface plasmon resonance (SPR)
experiments both CFH 1–6 and CFH 19–20 associated with
immobilized C3b, confirming the presence of independent
C3b-binding sites near both the N and C termini of CFH.
While CFH 8–20 bound immobilized C3b, CFH 8–11 and
CFH 15–18 did not [36]. Hence this study could not
confirm directly the existence of a third site, in the central
segment of CFH, able to bind C3b independently. On the
other hand, no CFH 12–14 construct was tested, thus it
remains possible that one or more of these three CCPs con-
tribute to a putative third C3b-recognition region. Accord-
ing to the same study [36] (Fig. 3) CFH 1–6 bound to
immobilized C3b but not to immobilized C3c or C3d (C3c
and C3d are non-overlapping proteolytic cleavage frag-
ments of C3b; C3d corresponds to the thioester domain of
C3b), while CFH 19–20 recognized C3d in addition to C3b
but not C3c [and the C-terminal C3b(C3d)-binding site
was mapped subsequently to CCP 20] [40]. Intriguingly,
CFH 8–20 bound to both C3c and C3d, suggesting [36]
that the inferred, third, C3b-binding site is specific for C3c.
A three-module, CCPs 10–12, C3b(C3c)-binding site would
explain most of these results, i.e. interference by the131X
antibody, the loss of C3b-affinity by CFH D6–10 (but not
the full activity displayed by CFH D11–15) and the results
obtained with CFH 8–11, CFH 15–18 and CFH 8–20; this
hypothesis requires testing with the appropriate constructs.
An alternative explanation consistent with the evidence is
that measurable affinity for C3c requires simultaneous
engagement of two subsites, one within CCP 10 and the
other within modules 16–18. In summary, two distinct
binding sites for C3b lie at the N (CCPs 1–4) and C termini
(CCP 20) of CFH; the latter is also able to bind C3d. Inter-
vening modules participate in the binding process, but evi-
dence for a distinct, third, C3b (C3c)-binding site remains
circumstantial.
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Binding sites of factor H for polyanions
Factor H binds to non-complement–activating surfaces
through interactions with polyanions. This is fundamental
to its ability to regulate complement on surfaces [1]. In early
studies, CFH CCP 13 (which is highly basic) and CCP 14
were implicated using a photoaffinity-tagging heparin
analogue [47]. However, experiments on CFHD13 and
CFHD11–15 [41] indicated that deletion of CCP 13 from
CFH results in only very slightly reduced ability to bind a
heparin-agarose column (and negligible loss of binding
to C3b-coated sheep erythrocytes). On the other hand,
CFHD6–10 showed significantly weaker heparin affinity [41]
implying a stronger GAG/sialic acid-binding site exists in the
6–10 region. A prominent role for CCP 7 in GAG binding
was confirmed subsequently because CFH 1–6, one of a
series of constructs generated in CHO cells [38] (Fig. 3),
barely bound heparin while CFH 1–7 was a good heparin-
binder. Furthermore CFH 1–6, 8–9 (i.e. a module 7-deletion
of CFH 1–9) lost all affinity for heparin [38]. Latterly, con-
structs of CFH 6–8 were shown to bind GAGs and GAG
analogues [27,48].
Interestingly, CFHD7 (and CFHD7D13) bound heparin
almost equally as well as CFH, so module 7 is not the only
one that binds polyanions [38]. That CFHD6–10, unlike
CFHD7 or CFHD7D13, eluted from a heparin-affinity
column at relatively low salt [41], suggests that modules 6, 8,
9 or 10 also participate in heparin binding. Some of these
modules could contribute to the same heparin-binding site
as CCP 7 or they could form a distinct, third site. A more
recent study of constructs CFH 8–9, CFH 9–11 and CFH
11–14 seems to support the notion of a third site centred on
Fig. 3. Summary of module-deletion/
truncations of complement factor H (CFH).
Complement control protein (CCP) modules
are shown as ovals within a cartoon-type
representation of each deletion/truncation
mutant. The black triangles indicate non-native
linker lengths in one mutant. ‘CA’ written
alongside indicates it has co-factor activity;
similarly ‘H’, ‘C3b’, ‘C3c’, etc. indicate the
mutant protein has binding affinity for
heparin-affinity resin, C3b, C3c, etc. (ESC3b
signifies sheep erythrocyte-bound C3b, as
opposed to fluid-phase or chemically
immobilized C3b); ‘PSE’: protects sheep
erythrocytes from complement-mediated lysis.
A strike-through means a particular activity was
investigated but found not to be measurable;
lower-case letters signify substantial reduction
in measured activity; SFTL, the four residues
specific to the C-terminus of CFH-like 1; ‘rr’,
non-native N-terminal sequence containing two
Arg residues. Superscripts refer to cited works
as follows: A, Alsenz et al. [31,32]; G, Gordon
et al. [34]; K, Kuhn [35]; J, Jokiranta et al. [36];
O, Ormsby et al. [37]; B, Blackmore et al.
[38,39]; H, Herbert et al. [27]; HW, Hellwage
et al. [40]; SP, Sharma and Pangburn [41]; and
P, Pangburn [42].
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module 9; CCPs 8–9 bind most strongly, followed by CCPs
9–11, while CCPs 11–14 did not bind heparin [37]. It is
worth noting that an artificial sequence containing two argi-
nine residues (EFTWPSRPSRIGT) was apparently included
at the N terminus (part of the cloning procedure) of CFH
8–9 and CFH 9–11; in combination with a native lysine
residue prior to the Cys(I) of CCPs 8 or 9, this introduces a
potential heparin-interacting artefact. Indeed, in a previous
study CFH 1–6, 8–9 (i.e. a construct containing both CCPs 8
and 9 but lacking CCP 7) had been shown not to bind
heparin [39].
In fact, the evidence suggests CCP 20 is the primary
heparin-binding determinant in CFHD7. The CFHD7D20
construct eluted from a heparin-affinity column at low salt
while CFH 18–20 bound relatively tightly [39]. Moreover,
non-heparin-binding CFH 1–5 was converted to heparin-
binding CFH 1–5, 20 by inclusion of CCP 20 in the construct
[39]. Human CFH from an individual with a mutation
(CFH-E1172Stop) resulting in a lack of module 20 bound
weakly to a heparin-affinity column [49]. Highly purified,
structurally characterized CFH 19–20 [25] bound well to a
heparin-agarose column. In summary, while GAG-binding
sites in module 7 (with contributions from CCPs 6 and 8)
and module 20 (with possible contributions from CCP 19)
are well established, current evidence for involvement of
either CCPs 9 or 13 is inconclusive.
C terminus of factor H recognizes C3b in the
context of the self-surface
The importance of the C-terminal heparin-binding site for
self versus non-self discrimination was shown by experi-
ments on CFHD6–10, CFHD11–15 and CFH 1–15. Of these
three constructs, only CFH 1–15 could not protect sheep
erythrocytes against lysis by human complement (Fig. 3)
[42]. In a dramatic illustration of the role played by CCPs 19
and 20, Ferreira et al. [50] showed that purified, Pichia
pastoris-produced, CFH 19–20 competitively inhibited the
action of CFH on cell surfaces. This double-module con-
struct overcame the protective effects of full-length CFH and
thereby promoted aggressive complement-mediated lysis of
sheep erythrocytes. Further support for a dominant role of
the CFH C terminus is provided by the ability of monoclonal
CCP 20-specific antibodies [51] to block interactions of
CFH with endothelial cells. Thus this C-terminal polyanion-
and C3b-binding site is critical for the ability of CFH to
recognize and protect host cells bearing sialic acids and
GAGs.
Besides disrupting the protection of normally non-
activating surfaces by full-length CFH, CFH 19–20 com-
pletely abolishes CFH binding to immobilized C3b (but not
to fluid-phase C3b) [50], despite the presence of the C3b-
binding site in CCPs 1–4. Moreover [51], CCP 20-specific
antibodies blocked CFH binding, in an enzyme-linked
immunosorbent assay (ELISA), to C3b and C3d as well as to
heparin (and to endothelial cells, as mentioned above). In
order to reconcile these intriguing results with the multiple
C3b- and GAG-binding sites identified by module-deletions
and CFH truncations, two models were proposed: (i) the C
terminus is unique among C3b-binding sites of CFH in
having a high affinity for cell surface-bound (csb) C3b (as
opposed to fluid-phase C3b or C3b immobilized artificially
on a chip or microtitre plate). The other C3b-binding site (in
CFH 1–4) has only poor affinity for C3b after the activated
C3 fragment has become attached to a surface; this CFH 1–4
site requires initial anchoring of CFH via the C terminus
before it can engage, to a significant extent, with its binding
site on csbC3b. Thus CFH 19–20 competes with the sole
csbC3b-binding site in full-length CFH for binding to
csbC3b. Because CFH 19–20 has no complement regulatory
region associated with it, the csbC3b to which it is bound is
not destroyed by factor I. Similarly, if the csbC3b-binding
site of CFH is blocked by an antibody then CFH will not
be able to bind to csbC3b. In the fluid phase, binding of
CFH 19–20 to C3b is functionally irrelevant as the CFH
N-terminal modules bind well elsewhere on fluid-phase C3b
and this latter interaction is sufficient for co-factor activity;
hence - in agreement with experimental evidence - CFH 19,
20 does not inhibit fluid-phase co-factor activity. The C ter-
minus probably recognizes a composite site consisting of
both GAGs and C3b; note that the C-terminal C3b-binding
site is the only one that also binds GAGs. (ii) According to an
alternative, or supplementary, model, the other CFH C3b-
binding site (in CCPs 1–4) is cryptic, only becoming avail-
able following occupation of the C-terminal site by C3b. The
C-terminal site binds initially to the thioester domain of C3b
inducing a conformational change within CFH. For
example, the binding site in CCPs 1–4 could be occluded
initially by interactions with other CCPs in a compact con-
formation of CFH. This notion of proximity between N- and
C-terminal modules tallies with SPR experiments showing
that CFH 1–7 binds full-length CFH on a Biacore chip [51]
and with low-resolution structural studies discussed earlier.
A problem with this notion of a cryptic site is that it predicts
that fluid-phase C3b, in the presence of full-length CFH and
an excess of CFH 19–20, will not be cleaved by factor I; this
is because the CFH 19–20 site on C3b would not be available
for binding by CFH. In fact, CFH 19–20 does not inhibit the
co-factor activity of CFH in the fluid phase. It therefore
remains necessary to invoke structural or accessibility differ-
ences between fluid-phase and csbC3b, as in model (i).
Mutations in CFH linked to atypical haemolytic
uraemic syndrome
Further support for a key role of the CFH C terminus in
complement regulation in vivo comes from studies of atypi-
cal haemolytic uraemic syndrome (aHUS) [52] (described
by Rodriguez de Cordoba and Goicoechea de Jorge in this
issue). The majority of aHUS-linked CFH mutations occur
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towards the C terminus, with CCP 20 being a hotspot [53].
Strikingly, a mouse model of aHUS was generated in CFH-
knock-out mice (that develop a different renal pathology,
dense deposit disease [45]) by transgenic expression of CFH
1–15 [54] (for further details see review by Pickering and
Cook in this issue). It was hypothesized that a predisposition
to aHUS is linked directly to an inability of mutant forms of
CFH either to bind properly to C3b(C3d) or to recognize
polyanionic markers on non-activating surfaces (or a dimin-
ishment of both these roles). This hypothesis has been tested
by mutagenesis and structural studies.
Table 1 lists laboratory-generated and naturally occurring
CFH mutants containing sequence changes within CCPs 19
and 20, all of which have been tested for function. Some were
expressed recombinantly within the contexts of partial ver-
sions of CFH such as CFH 19–20 or CFH 8–20, hence there
is variation in the extent to which other binding sites within
the protein can contribute to the functional outcome. Some
changes coincide with aHUS-linked mutations while others
were designed to identify residues participating in functional
sites.
All mutated proteins for which C3b(C3d)-binding data are
reported exhibit decreased affinity; K1186A, which is not
aHUS-linked, is the exception. Most mutants display loss or
reduction in affinity for heparin-affinity resin and for human
umbilical vein endothelial cells (exceptions are R1182A,
K1186A, S1191L and V1197A). Thus all the aHUS-linked
mutants tested for function exhibited a deficiency in binding
to either C3b(C3d) or GAGs, and in several cases to both.
Pathophysiological insights based solely on the data in
Table 1 are limited for several reasons. (i) No distinction was
made between perturbation of a specific binding site and
widespread structural disruption of the module. (ii) Contra-
dictory results were obtained, e.g. W1183L in the context of
CFH 19–20 dimerized [as judged by mobility on sodium
dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-
PAGE)] and the dimer binds tightly to a heparin-affinity
column; yet W1183L in the context of CFH 8–20 binds more
weakly to heparin-affinity resin than the native-sequence
8–20 construct. (iii) Glycosaminoglycans are diverse; their
levels and patterns of sulphation, for example, vary between
tissue-type and over the course of development and ageing
[61]. This raises a critical issue that has repercussions for the
organ-limited nature of particular complement-associated
diseases: can the ability of CFH to protect host surfaces be
attributed to specific GAG-recognition processes [62]?
Unfortunately, heparin-affinity chromatography is a crude
probe of the capacity to recognize specific surface polyanions.
Thus, unfortunately, it is difficult to test directly the hypoth-
esis that mutations in CFH predispose to aHUS if they disrupt
regions of CFH involved in recognition of specific GAG-
sulphation patterns in the glomerulus (for example).
In an attempt to deal with some of these issues, the 3D
structural basis of GAG recognition by CCPs 19 and 20 was
investigated using nuclear megnetic resonance (NMR) [25]
and crystallography [26]. The two modules are organized
in the linear, end-to-end arrangement observed in other
structures of CCP-module pairs. A model GAG
compound - pure, fully sulphated heparin tetrasaccharide
(dp4), enzymatically cleaved from heparin - was titrated
into the CFH 19, 20 sample and the NMR frequencies, or
chemical shifts, of protein backbone atoms were monitored
for perturbations. The presence of bound dp4 induces
changes in the magnetic field experienced by nearby nuclei
and thus amino acid residues in or near the binding site will
resonate with slightly different chemical shifts. A surface
patch of CFH 19, 20 residues was thus implicated in binding
to dp4. Strikingly, these coincided well with aHUS-linked
mutations [25]. For example, R1182, W1183, T1184, E1198
and R1215 (see Fig. 4) showed significant chemical shift
perturbations. Thus, these experiments support a disease
model in which dysfunctional CFH fails to protect fully the
GAG-rich layers of the glomerular basement menbrane from
complement activation.
A credible, theoretical docking exercise [25] placed C3d
on the reverse face, relative to the GAG-recognition site, of
CFH 20 (i.e. on the back-face as viewed in Fig. 4). None the
less, in reality, C3d (and C3b) binding might be disrupted by
aHUS-linked mutations, as suggested by Jokiranta et al. [26].
To investigate this possibility, the location of residues listed
in Table 1 was mapped onto the 3D structure (Fig. 4). The
role of R1210 is difficult to assess from the data because of
the disulphide-forming potential of R1210C, but its location
on the back-face (Fig. 4) is consistent with the putative loca-
tion of the C3d-binding site based on the outcome of the
docking studies. On the other hand, five side-chains, forming
a band across the front face of CCP 20 (Fig. 4), were also
implicated in C3d binding according to mutagenesis studies.
Four of these residues are implicated additionally in binding
to a heparin-affinity column, and also appear in the list of
significantly perturbed chemical shifts obtained from dp4
NMR-titration experiments. One possible explanation for
these apparently confusing results is that CFH 19–20 has
GAG- and C3d(C3b)-binding sites that are sufficiently close
to interfere or co-operate with one another depending on the
nature of the ligand tested (e.g. heparin versus a physiological
GAG and C3b versus C3d) and the order of binding events.
Thus heparin inhibits binding of C3d to CFH 15–20 while
C3d enhances binding of native-sequence CFH 15–20 to
heparin [49]. These observations are not inconsistent with
the intuitively feasible hypothesis that a tertiary complex
containing GAGs, C3b and CFH forms during the process of
complement regulation on self-surfaces. A caveat to inter-
pretation of these studies is that electrostatic ‘steering inter-
actions’ (as probed here by mutating Arg and Lys residues to
uncharged residues, or potentially neutralizing their side-
chains by addition of a polyanion such as heparin) may
represent just one step in the multi-step process whereby
C3d interacts with CCPs 19–20. Electrostatic steering [63]
could enhance the number of productive encounters
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Table 1. Mutations in complement control proteins (CCPs) 19 and 20 of complement factor H (fH).
Mutation Source of protein
aHUS
link? CA?
Binding to
C3b(C3d) GAG HUVEC
W1157R In context of fH 8–20
(Baculovirus) (Jz 2006)
Yes NR << to C3b/C3d in
CPA; none by SPR;
Slight reduction
in heparin binding
Slightly
reduced
E1172-stop Purified from heterozygous
patient (M 2003; J 2005)
Yes NR << to C3b by SPR Slightly weaker
than WT
No
R1182A In context of fH 19–20
(Pichia pastoris) (J 2006)
Resembles
R1182S
NR < to C3d in CPA; by SPR,
sl. < C3b, < C3d
Binds to heparin-
affinity column
NR
W1183L Ex heterozygous patient
(and ex COS cells)
(S-C 2002,4)
Yes Yes* < to C3b in CPA NR NR
W1183L In context of fH 8–20
(Baculovirus) (Jz 2006)
Yes NR < to C3b and C3d (SPR);
< to C3b/C3d in CPA
Binds weakly to
heparin column
Weak
W1183L In context of fH 19–20
(P. pastoris); note - dimer on
SDS-PAGE (J 2006)
Yes NR < to C3d in CPA < to
C3d; anomalous result
for C3b by SPR
Dimer binds more
tightly than
native fH 19–20
NR
K1186A In context of fH 19–20
(Pichia pastoris) (J 2006)
No NR Full binding to C3b in
CPA; SPR NR
Similar heparin
affinity to fH 19–20
NR
K1188A In context of fH 19–20
(Pichia pastoris) (J 2006)
No NR < to C3d in CPA; < to
C3b and C3d by SPR
sl < binding than
fH 19–20 to hep.
NR
S1191L Ex heterozygous patient (H2006) Yes * NR Full binding to
heparin column
NR
S1191L, V1197A Ex heterozyg. patient (and in
fH 18–20 context) (H 2006)
Yes * < to C3b and C3d by SPR Full binding to
heparin column
NR
V1197A Ex heterozyg. and also ex
hemizyg. patients (H 2006)
Yes * NR Full binding to
heparin column
NR
V1197A Ex homozygous patient (and ex
COS cells) (S-C 2002,4)
Yes Yes* < to C3b in CPA NR NR
V1197A In context of fH 8–20
(Baculovirus) (Jz 2006)
Yes NR < to C3b/C3d-coated
plates, and by SPR
Binds weakly to
heparin column
Weak
E1198A In context of fH 19–20
(Pichia pastoris) (J 2006)
Yes NR < to C3d in CPA SPR: sl
< to C3b, spurious C3d
> to hep. column
cf fH 19–20
NR
E1198K Ex heterozygous patient
(V-S 2006)
Yes * NR NR Weak
R1203E, R1206E,
R1210S, K1230S,
R1231A
In context of fH 15–20
(P. pastoris) (HW 2005)
R1210S
Resembles
R1210C
NR Significantly < to C3d
and C3b (by SPR)
No binding to
heparin column
No
R1203E, R1206E,
R1210S
In context of fH 15–20
(P. pastoris) (J 2005)
See above NR NR No binding to
heparin column
No
R1210C Ex heterozyg. patient (di-S with
other proteins) (& ex COS
cells) (S-C 2002, 2004)
Yes Yes* < to C3b in CPA NR NR
R1210C Ex heterozyg. patient and in
context of fH 8–20
(Baculovirus)
(M 2003; Jz 2006)
Yes NR < to C3b/C3d-coated
plates; < to C3d
by SPR
Binds weakly to
heparin column
Weak
R1215G In context of fH 8–20
(Baculovirus) (M 2003)
Yes NR Significantly < binding
to C3d by SPR
Binds weakly to
heparin column
Weak
P1226S In context of fH 8–20
(Baculovirus) (Jz 2006)
Yes NR Not to C3b/C3d-coated
plates; none, by SPR
Binds weakly to
heparin column
NR
K1230S, R1231A In context of fH 15–20
(P. pastoris) (J 2005)
No NR NR Binds hep. column
equal to fH 15–20
Weak
aHUS: atypical haemolytic uraemic syndrome; GAG, glycosaminoglycan; HUVEC, human umbilical vein endothelial cell; NR, not reported; CPA,
coated plate assay; SDS-PAGE: sodium dodecyl sulphate-polyacrylamide gel electrophoresis; SPR, surface plasmon resonance; sl, slight; hep, heparin; ex,
from; <, reduced binding; CA, co-factor activity; *reduced ability to protect sheep erythrocytes from complement-mediated haemolysis. Superscripts
refer to cited work as follows: Jz 2006, Jozsci et al. [55]; M 2003, Manuelian et al. [56]; J 2005, Jokiranta et al. 2005 [49]; J 2006, Jokiranta et al. 2006 [26];
S-C 2002, 2004, [57,58]; H 2006, Heinen et al. [59]; V-S 2006, Vaziri-Sani et al. [60].
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between a pair of protein molecules by influencing their
orientations as they approach one another, but the eventual
complex could be stabilized by other interactions involving
an entirely different set of side-chains. Another factor that
complicates interpretation is the putative oligomerization of
CFH that could be important and may occur via the
C-terminus [26]. Thus despite much recent progress, in the
absence of detailed thermodynamic studies of binding and
3D structures of binary and tertiary complexes, the picture
remains obscured.
SNPs in CFH linked to age-related macular
degeneration
Patients suffering from dense deposit disease, a rare but
serious form of glomurulonephritis, often develop the soft
ocular drusen regarded as a hallmark of early age-related
macular degeneration [64] (AMD), which is a leading cause
of geriatric vision-loss. The recently discovered links
between the Y/H 402 polymorphism in CCP 7 of CFH and
both dense deposit disease [65] and AMD [66] hints at the
physiological importance of this second (after CCP 20)
polyanion-binding site in CFH. The at-risk sequence varia-
tion is also present in CFH-like 1, where module 7 represents
the sole polyanion binding site. This GAG-binding module
has been reported additionally to participate in binding sites
for CRP [67], fibromodulin [68], DNA [68] and various
pathogen-borne proteins [67,69,70].
Structural and chemical shift perturbation studies of CCP
7 - similar to those carried out on CFH 19–20 - revealed
that the H/Y 402 side-chain is positioned in order to con-
tribute specificity to a GAG-binding groove [27]. Working
with the single module, Y402 CCP 7 bound significantly
more strongly than H402 CCP 7 both to a heparin-affinity
column and to dp4. This appears to support the case for a
causal link between the polymorphism and a mechanism for
AMD involving insufficient complement regulation in the
ageing choroid. When examined in the context of the triple-
module CFH 6–8, however, the two variants bound equally
well to some GAGs [27] but differently to others [48], with
either variant binding more tightly depending upon the
GAG tested. Both Y402 and H402 versions of full-length
CFH bound equally well to a series of fully sulphated heparin
fragments and (as might have been predicted from the afore-
mentioned results obtained for CFHD7) to a heparin-affinity
column [27,68,71,72].
In all probability, what these results illustrate is that the
CFH–GAG interaction is both dual-site (i.e. involves two
physiologically relevant GAG-binding sites on CFH) and
tissue-specific. The results obtained with isolated CCP 7 in
complex with a chemically defined heparan sulphate ana-
logue, together with the data for interaction of CFH 6–8 with
a range of heterogeneous GAGs, indicate strongly that the
disease-linked polymorphism is tweaking the GAG-(self)-
recognition capabilities of CFH in a subtle fashion not
apparent in the test tube with full-length CFH and the ‘blunt
instrument’ of heparin. Such a conclusion is supported by
the detailed picture of protein–sugar interactions provided
by the crystal structure of CFH 6–8 in complex with sucrose
octasulphate [28]. A subtle difference between the two
allotypic variants is consistent with the H402 (at-risk)
variant of CFH - present in 35% of Western populations -
functioning adequately until at least old age. Indeed, the
H402 variant is less tightly sequestered than the Y402 variant
by the M6 protein of Streptococcus pyogenes and might confer
an evolutionary advantage in this respect [72].
Consistent with a ‘GAG hypothesis’ for a causal link with
AMD there is also evidence for differential binding of the
Fig. 4. Amino acid residue positions of
mutations listed in Table 1 within the structure
of complement factor H (CFH) 19, 20. The
structure of CFH 19, 20 is drawn as a cartoon
in PyMol (see legend to Fig. 2). Mutated
side-chains are labelled (and in parentheses if
they are likely to be structurally critical) and
drawn and their exposed surfaces are rendered
(dark blue if they are positively charged,
otherwise cyan). Underlining indicates that
mutations in the residue concerned are linked
to atypical haemolytic uraemic syndrome. The
effect on function - where measured - is
indicated by symbols (see key), except for
residues likely to be critical for structural
integrity.
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Y/H 402 variants to cell surfaces. Flow cytometry and con-
focal laser scanning microscopy revealed a slightly lower
binding of the H402 variant to retinal pigment epithelial
cells and to endothelial cells, and indeed (in the context of
CFH-like 1) the H402 variant has reduced co-factor activity
at the cell surface even though there is no difference in fluid-
phase co-factor activity between the two variants [73]. In
another flow cytometry study the H402 variant exhibited
higher binding to necrotic Jurkat T cells, which may reflect a
measured difference in DNA-affinity between the variants
(with H402 CFH 6–8 binding to DNA more tightly than Y
402 CFH 6–8) [68].
Controversy surrounds the effects of the polymorphism
on the affinity of CFH for CRP as measured by SPR or by
ELISA. Five reports concur that the H402 allotypic variant
(within the context of full-length CFH, CFH-like 1, CFH 5–7
or CFH 6–8) is the weaker CRP binder [27,68,71–73]. Pre-
vious work showed that CRP is more abundant in the eyes of
AMD patients with the H402 variant of CFH than in those
with the Y402 variant [74] and that CRP is present in drusen
[68,74]. It has been suggested that CFH recognizes CRP
borne on the membranes of apoptotic cells and acts to
ensure that apoptotic cell clearance proceeds in a non-
inflammatory setting [75]. Overlap has been reported for
CRP- and GAG-binding sites on CCP 7 [67], suggesting that
the relative affinities for these two ligands might be critical
for CFH function at self-surfaces in situations where both
ligands are encountered; if the Y/H 402 side-chain contrib-
utes to both sites it could be a key player in this respect. So a
‘GAG hypothesis’ and a ‘CRP hypothesis’ need not be mutu-
ally exclusive. However, a study by Hakobyan et al. [76] casts
doubt on the relevance of the CFH–CRP interaction. In the
hands of these authors, CFH interacts with CRP only under
circumstances where the CRP pentamer is disrupted
through Ca2+ ion-removal, a situation that would never
prevail in physiological circumstances.
Conclusions
Taking all these data together, a mechanism for CFH is
emerging. The two ends of CFH (modules 1–7 and modules
19–20) contain all the proven discrete binding sites and are
also the sites of most disease-linked sequence variations. The
modules joined by long linkers towards the centre of CFH
(CCPs 12–14) allow CFH to kink so that these two ends are
brought into proximity. The C-terminal modules are the
only ones with the potential to bind to a composite site
consisting of C3b and the polyanions on the self-surface
to which C3b is attached, and hence are dominant in
distinguishing self-surfaces from non-self (complement-
activating) ones. The N-terminal three or four CCPs, like
other similar blocks of CCPs in other RCAs (e.g. CD46,
CD55, CD35) are able to perform the task of disrupting the
surface-associated C3/C5 convertases once the CFH is
anchored in place by its C-terminus. To position correctly
the N-terminal modules in the GAG-convertase-CFH
complex, a further interaction of CFH with GAGs is medi-
ated by the specific recognition capabilities of CCP
7 - indeed, this module could act as a ‘proof-reader’ to make
it more difficult for bacteria to emulate the chemistry at
self-surfaces. Further understanding probably depends on
more detailed binding studies of chemically pure GAG ana-
logues combined with 3D structural studies of the protein–
protein and protein–carbohydrate complexes.
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